EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Lung Cancer: Targeted Therapy in 2025

Nicole Bouchard iD, Nathalie Daaboul

Current Oncology · 02.03.2025 · 32 (3) · 146

DOI: 10.3390/curroncol32030146 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 02.03.2025. Verfasst von Nicole Bouchard und 1 weiteren Autor:innen. Beteiligte Einrichtung: Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada. Hauptthemen laut MEDLINE: Lung Neoplasms, Molecular Targeted Therapy, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer treatment has changed in the last twenty years since the discovery of EGFR mutations. In this article, we will review the current state of the art for non-small cell lung cancer (NSCLC) actionable genomic alterations (AGA). AGAs are mostly found in lung adenocarcinomas, a subtype of non-small cell lung cancers. We will focus on the current treatment for EGFR mutations, ALK fusions, ROS1 fusions, BRAF V600E mutations, MET exon 14-skipping mutations, RET fusions, KRAS G12C mutations, ERBB2 mutations (also called HER2 mutations), and NTRK fusions. We will also touch on the key toxicities associated with these medications. Treatments are mostly available for the metastatic stage, but we will also discuss adjuvant therapy for EGFR mutations and ALK fusions, as well as stage III post-chemoradiotherapy treatment for EGFR lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsMolecular Targeted TherapyCarcinoma, Non-Small-Cell LungHumansMutationErbB Receptors

Stichwörter der Autor:innen

lung cancermolecular testingtargeted therapy

Substanzen

ErbB Receptors

Autor:innen und Institutionen

  • Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
  • Centre Intégré de Cancérologie de la Montérégie, Université de Sherbrooke, Longueuil, QC J4V 2H1, Canada.

ORCID-Profile: Nicole Bouchard

Zitieren

APA

Bouchard, N., & Daaboul, N. (2025). Lung Cancer: Targeted Therapy in 2025. Current Oncology, 32(3), 146. https://doi.org/10.3390/curroncol32030146

Vancouver

Bouchard N, Daaboul N. Lung Cancer: Targeted Therapy in 2025. Current Oncology. 2025;32(3):146. doi:10.3390/curroncol32030146

BibTeX
@article{Bouchard2025,
  author = {Bouchard, Nicole and Daaboul, Nathalie},
  title = {Lung Cancer: Targeted Therapy in 2025},
  journal = {Current Oncology},
  year = {2025},
  volume = {32},
  number = {3},
  pages = {146},
  doi = {10.3390/curroncol32030146}
}
Kostenlos starten →